Clinical Trials: Fabry Disease

Birmingham : University of Alabama at Birmingham

Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease

Phoenix : AKDHC

A Multi-center, Open-Label, Randomized study evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients with Fabry Disease.

Aurora : University of Colorado Health Sciences Center

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Atlanta : GSK Investigational Site Updated

Open-Label Phase 3 Long-Term Safety Study of Migalastat

Decatur : Emory University

Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease

Decatur : Emory University

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Iowa City : University of Iowa Children's Hospital

Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease

Kansas City : University of Kansas Medical Center

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Cambridge : Participation in this study is not limited to this facility; facilities not yet active may enroll upon identification of a patient

A Study of the Effects of Fabrazyme (Agalsidase Beta) on Mother's Lactation and on the Growth, Development and Immunologic Response of Their Infants

Cambridge : Registry participation is worldwide and not limited to this facility; facilities not yet active may enroll upon identification of a patient.

Fabry Disease Registry

Minneapolis : University of Minnesota

Natural History and Treatment Outcomes(Changes) in Fabry Renal Disease Study

Minneapolis : Universtity of Minnesota, Department of Pediatric Nephrology

Natural History and Treatment Outcomes(Changes) in Fabry Renal Disease Study

Minneapolis : University of Minnesota, Fariview

Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease

Columbus : Eye and Ear Institute

Establishment of Biomarkers for Fabry Disease

Pittsburgh : Children's Hospital of Pittsburgh

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Springfield : O & O Alpan LLC

Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease

Springfield : O & O Alpan LLC

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Milwaukee : Children's Hospital of Wisconsin, Genetics Center

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Pergamino : Instituto de Nefrologia Pergamino SRL

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Parkville : Royal Melbourne Hospital

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Perth : Royal Perth Hospital

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Graz : Universitätsklinikum für Neurologie

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Vienna : Medical University of Vienna

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Antwerpen : Universitair Ziekenhuis Antwerpen, Konigin Paola Kinderziekenhuis

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Edegem : Universitair Ziekenhuis Antwerpen

Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease

Porto Alegre : Hospital de Clinicas de Porto Alegre

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Sao Paulo : Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Montreal : Hopital du Sacre-Coeur

Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease

Zagreb : Department of Neurology, University Hospital Sestre Milosrdnice

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Copenhagen : Righospitalet

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Bordeaux : Hopital Pellegrin

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Lille : Hopital Calude Huriez

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Lyon : Hopital Neurologique de Lyon, Service d'urgences Neurovasculaires

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Tblisi : Department of Neurology, S. Khechinashvili University clinic of Tbilisi state medical university

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Bayreuth : Department of Neurology, Klinikum Hohe Warte

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Berlin : Charite Campus Benjamin Franklin, Dept. of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Celle : Department of Neurology, Allgemeines Krankenhaus Celle

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Chemnitz : Department of Neurology, Klinikum Chemnitz gGmbH

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Dresden : Department of Neurology, Universitaetsklinikum Carl Gustav Carus

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

View More »

Duesseldorf : Heinrich-Heine-University Duesseldorf, Dept. of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Giessen : University of Giessen-Marburg Dept. of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Hamburg : Department of Neurology, Universitaetsklinikum Hamburg-Eppendorf

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Jena : Department of Neurology, Universitaetsklinikum Jena

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Leipzig : Department of Neurology, Universitaetsklinikum Leipzig

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Mainz : Universitätsklinikum Mainz, Zentrum für Kinder- und Jugendmedizin

Home Therapy With Replagal in Fabry Disease

Mühlhausen / Thürigen : Dept. of Neurology, Ökumenisches Hainich Klinikum gGmbH

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

München : Ludwig-Maximilians-University of Munich, Klinikum München-Großhadern, Dept. of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Tuebingen : Department of Neurology, University Tuebingen

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Ulm : University of Ulm, Department of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Firenze : Azienda Ospedaliera Universitaria Careggi

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Roma : Policlinico Universitario Agostino Gemelli

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Abeno-ku : Osaka City University Hospital

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Chuo-ku : Niigata University Medical and Dental Hospital

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Nishi : Jikei University Hospital

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Amsterdam : Academisch Medisch Centrum (AMC)

Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease

Warsaw : Institute of Psychiatry and Neurology, Dept. of Neurology

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Lisboa : Centro Hospitalar de Lisboa Central, Servico de Neurologia

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

Taipei City : Taipei Veterans General Hospital

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

London : The Royal Free Hospital

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

London : National Hospital for Neurology and Neurosurgery Queen Square

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Salford : Hope Hospital, Salford Royal NHS Foundation Trust

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease